

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**MTA beta interferon and glatiramer acetate for treating
multiple sclerosis (review of TA32)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During consultation on the draft scope a consultee noted that there may be regional differences in access to medical assessment, specialist health professionals and rehabilitation care.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

In general, regional differences in care would not be considered an equality issue. However, the Committee should discuss whether its recommendations have the potential to indirectly discriminate against some people. For example, if the guidance recommends that care is provided only in a specialist centre, people who are unable to travel due to a disability may find it difficult to access treatment.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Melinda Goodall

Date: 07/01/2016